Shanghai RAAS has continuously received a Wind ESG AA rating, with a comprehensive score of 8.70

According to Tongbi Finance, on June 5, 2026, Shanghai RAAS Blood Products Co., Ltd. (stock abbreviation: Shanghai RAAS, code: 002252.SZ) received a Wind ESG rating of AA, unchanged from the previous period. The company's overall score is 8.70, higher than the biotechnology III industry average of 6.37. It ranks 2nd among 154 companies in the biotechnology III industry, placing it in the top 1.30% of the industry. The scores for the environmental, social, and governance dimensions are 7.75, 8.12, and 8.36, respectively.

Compared to the previous rating, the overall score increased from 8.09 to 8.70, an improvement of 0.61 points. Among these, the contribution from management practices rose from 5.10 to 5.71, an increase of 0.61 points; the contribution from controversy events remained stable at 3.00. In terms of dimensions, the environmental dimension improved by 0.80 points, the social dimension by 0.96 points, and the governance dimension by 0.72 points.

Rating Observation

In the environmental dimension, the company demonstrated strong system construction and quantitative management capabilities, achieving significant progress in waste management and energy management. In waste management, the company, led by the Environmental Safety Management Department, established a comprehensive management system covering the entire process from production to disposal and set up an EHS management committee that reports directly to the chairman. Currently, 60% of operational sites have obtained ISO 14001 certification. Through the alcohol waste membrane concentration treatment system, the company achieved a 43.24% reduction in hazardous waste alcohol and recovered ethanol resources, reducing hazardous waste disposal costs by approximately 1.588 million yuan. In energy management, the company obtained ISO 50001 certification and, in conjunction with green electricity direct procurement and green certificate supplementation, increased the proportion of green electricity to 20%, meeting the annual target on schedule. Additionally, the company established annual energy goals and indicators and continuously optimized energy efficiency through energy-saving renovations and energy monitoring systems, with some projects achieving quantifiable carbon reductions. Although the disclosure of climate change issues includes greenhouse gas emission data, there is still room for improvement in information regarding Scope 3 emissions, carbon neutrality certification, and risk quantification analysis.

In the social dimension, the company demonstrated systematic capabilities in product quality management, R&D innovation, and employee welfare. The company has established a quality management system covering the entire group, based on GMP standards and referencing ISO 9001 standards, with all production bases achieving 100% GMP certification to ensure product quality and safety. In terms of R&D, the company invested 2.234 billion yuan during the reporting period, accounting for 3.04% of operating revenue, with a total of 99 effective patents and R&D staff accounting for 6.5%. Regarding employee welfare, the company provides additional paid annual leave, blood donation leave, and elderly care leave, with an employee satisfaction survey score of 4.6 (out of 5), and 87.5% of employees giving high ratings. Furthermore, the company achieved 100% completion of 4 key quality control indicators through its drug vigilance system, exceeding the established target of 95%. Nevertheless, there is still room for improvement in the completeness of information regarding R&D management goals, planning, and related system certifications In terms of governance, the company excels in board independence, diversity, and anti-corruption management. The proportion of independent directors on the board is 36.36%, with female directors accounting for 45.45%, and the CEO does not concurrently serve as the chairman, reflecting the independence and diversity of the governance structure. The proportion of independent directors on the audit committee, compensation committee, and nomination committee is 66.67%, with the audit committee chair being an independent non-executive director, further strengthening the governance checks and balances. In terms of anti-corruption management, the company has established several systems, including the "Anti-Corruption and Anti-Commercial Bribery System" and the "Whistleblower Management and Protection System," which are supervised by the board's audit committee. Additionally, anti-corruption and compliance training is conducted annually for all employees, with a total of 10 training sessions held during the reporting period, covering all staff. Although the company's governance disclosure is relatively comprehensive, information regarding the effectiveness evaluation of the board and the risk management committee has not yet been disclosed, and risk control measures for antitrust and fair competition need further improvement.

Content generated by AI on June 5, 2026, please verify important information